Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
Press Release
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
Exclusive licensee for China, Ocumension, received positive pre-submission regulatory feedback from the Chinese Center for Drug Evaluation (CDE) for NCX 470
Based on this feedback, Ocumension intends to proceed with the New Drug Application (NDA) submission in China
Submission should follow shortly after NCX 470 NDA to the U.S. Food and Drug Administration (FDA), expected summer 2026
June 18, 2026 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (PARIS:FR, ALCOX)), an international ophthalmology company, today announced that its exclusive licensee in China, Ocumension Therapeutics, has received positive pre-submission regulatory feedback from the Chinese
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.